CHEK1 and pancreatic neoplasm: Furthermore, G2/M checkpoint abrogation using checkpoint kinase 1 (CHK1) inhibitors is known to increase the RT efficacy in preclinical models of pancreatic cancer [8], colorectal cancer [9], bladder cancer [10], and TNBC [11].